Sigilon Therapeutics Ownership
The market capitalization of Sigilon Therapeutics is $56.22 Million. Over half of Sigilon Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in stocks such as Sigilon Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Sigilon Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Sigilon |
Sigilon Stock Ownership Analysis
About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.25. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sigilon Therapeutics recorded a loss per share of 14.83. The entity had not issued any dividends in recent years. The firm had 1:13 split on the 23rd of May 2023. Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people. To find out more about Sigilon Therapeutics contact MBA MD at 617 336 7540 or learn more at https://www.sigilon.com.Sigilon Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sigilon Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sigilon Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sigilon Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eli Lilly Co over a year ago Purchase by Eli Lilly Co of 1718493 shares of Sigilon TherapeuticsInc | ||
Kowalsky Matthew Paul over a year ago Disposition of 1925 shares by Kowalsky Matthew Paul of Sigilon TherapeuticsInc subject to Rule 16b-3 | ||
Yuan Qing Sarah over a year ago Exercise or conversion by Yuan Qing Sarah of 2884 shares of Sigilon TherapeuticsInc subject to Rule 16b-3 | ||
Eli Lilly Co over a year ago Sigilon TherapeuticsInc exotic insider transaction detected | ||
Philip AshtonRickardt over a year ago Acquisition by Philip AshtonRickardt of 115000 shares of Sigilon TherapeuticsInc subject to Rule 16b-3 |
Sigilon Therapeutics Outstanding Bonds
Sigilon Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sigilon Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sigilon bonds can be classified according to their maturity, which is the date when Sigilon Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| SIERRA 6 15 JUN 28 Corp BondUS82653LAA98 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |